1. We will recruit 30 probands who meet DSM-IV inclusion criteria for a primary psychotic disorder or mood disorder with psychotic features: schizophrenia, schizoaffective disorder, delusional disorder, bipolar I disorder, psychotic depression, post…
ID
Source
Brief title
Condition
- Schizophrenia and other psychotic disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
1. The identification of genetic variation in probands and their family members
2. Clinical characterization of the probands and their family members
Secondary outcome
n/a
Background summary
With recent technological developments in medicine, it has become possible to
investigate the genetic basis of illnesses and disorders. Many scientists
worldwide investigate the genetic underpinnings of psychiatric disorders such
as depression and psychosis. It has proven to be difficult to pinpoint the
exact area in the genetic material that is responsible for the vulnerability
for psychiatric disorders. It is likely and generally assumed that the
emergence of symptoms in psychiatry involves a complex interaction between a
person*s genes and the circumstances and events one experiences in his or her
life.
Genetic material is inherited from both parents and is partly similar in
members of the same family. Therefore, it is possible to compare the genetic
material of several family members in order to identify parts of the genetic
material that may be involved in the emergence of psychiatric symptoms or
disorders. In this study, we ask the question if there are areas in the genetic
material that correlate with the expression of psychiatric symptoms.
Study objective
1. We will recruit 30 probands who meet DSM-IV inclusion criteria for a primary
psychotic disorder or mood disorder with psychotic features: schizophrenia,
schizoaffective disorder, delusional disorder, bipolar I disorder, psychotic
depression, post-partum psychosis. These probands will be clinically assessed
with blood drawn for the analysis of DNA and RNA. The DNA will be analyzed
with high-throughput sequencing and micro-array based comparative genomic
hybridization to examine these subjects for the presence of potentially
etiologic genetic variations. RNA expression analyses will investigate the
impact of the genetic variants on gene transcription.
2. We will recruit up to 300 first-, second-, or third degree biological
relatives of these probands who may or may not be affected with psychosis.
These subjects will also be clinically assessed with blood drawn for the
analysis of DNA and RNA. The DNA will be analyzed with high-throughput
sequencing and micro-array based comparative genomic hybridization to examine
these subjects for genetic variations observed in the probands. RNA expression
analyses will investigate the impact of the genetic variants on gene
transcription. A selection of patients and family members will be asked to
cooperate with a skin biopsy in order to map the biological effect of the
genetic difference on (nerve) cell characteristics.
3. Furthermore, we will recruit 20 probands and both their unaffected
biological parents for de novo genetic analysis. These subjects will also be
clinically assessed with blood drawn for the analysis of DNA and RNA. The DNA
will be analyzed with high-throughput sequencing and micro-array based
comparative genomic hybridization to examine these subjects for genetic
variations observed in the probands. RNA expression analyses will investigate
the impact of the genetic variants on gene transcription.
Study design
A naturalistic, single-center study focused on identifying genetic risk factors
for psychosis in patients and their family members.
Study burden and risks
There are no direct benefits connected to participation in this study.
Participation helps physicians and researchers to gain more insight into
biology of psychiatric disorders. This may lead to the development of new forms
of treatment. A downside of participation is that it will take about 2 hours of
the time of each participant. Furthermore, on one occasion a sample of blood is
drawn. A selection of patients and family members will be asked to cooperate
with a skin biopsy in order to map the biological effect of the genetic
difference on (nerve) cell characteristics. This is a minimally invasive
procedure that is not very painful, but might produce some discomfort. It is
possible that some scarr tissue will form and a small chance to develop an
infection. An MRI will be performed to exclude the possibility that the
neuropsychiatric symptoms arise from structural brain abnormalities.
'S Gravendijkwal 230
Rotterdam 3000CA
NL
'S Gravendijkwal 230
Rotterdam 3000CA
NL
Listed location countries
Age
Inclusion criteria
A. Inclusion criteria for probands
1. All subjects must give signed, informed consent.
2. Probands must have a DSM-IV consensus diagnosis of primary psychotic disorder or mood disorder with psychotic features (schizophrenia, schizoaffective disorder, delusional disorder, bipolar I disorder, psychotic depression, post-partum psychosis). A concurrent diagnosis of idiopathic seizure disorder or learning disability will not be an exclusion factor. Accordingly, subjects with mild MR (as determined clinically, FIQ>=55) will be included, if their psychiatric symptoms and history can be clearly established.
3. Subjects must be over 18 years of age at interview, male or female.;B. Inclusion criteria for informants
1. The informant will have known the subject for at least two years, be familiar with their psychiatric history, and have at least one hour of contact per week with the proband (first-degree family members preferred). As for the probands, informants must give signed, informed consent and be over 18 years of age at interview.
2. Exclusion criteria are the same as for the probands given above.;C. Inclusion criteria for family members of probands
1. First-, second-, or third degree biological family member of participating probands. As for the probands, family members must give signed, informed consent and be over 18 years of age at interview.
2. Exclusion criteria are the same as for the probands given above.
3. Family members may, but are not required, to meet criteria for a DSM-IV consensus diagnosis of primary psychotic disorder or mood disorder with psychotic features.
Exclusion criteria
1. Unable to give informed consent to all aspects of the study.
2. Unable to speak and be interviewed in Dutch or English (to ensure validity of the interviews).
3. Psychosis is deemed secondary to substance use by the consensus diagnostic procedure because psychotic symptoms are limited to periods of likely intoxication or withdrawal, or there are persistent symptoms which are likely to be related to substance use (i.e., increasing paranoia after years of amphetamine use; symptoms limited to visual hallucinations after extensive hallucinogen use).
4. The seizure disorder is deemed secondary to causative factors, such as medication (e.g., clozapine), head injury, psychogenic polydispsia, or alcohol withdrawal.
5. Subjects with severe mental retardation (MR).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL32184.078.10 |